Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Terry Smith

Nurse Practitioner Naples, FL Nurse Practitioner

NPI 1508952292 CMS profile 10721643

6605 Hillway Cir Ste 101, Naples, FL 34112

Open in the dashboard

General payments

$16,960

835 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terry Smith of Naples, FL is reported in the CMS Open Payments database as having received $16,960 across 835 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,246 146
2024 General $3,352 178
2023 General $4,160 198
2022 General $4,062 185
2021 General $2,141 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terry Smith
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Terry Smith were reported at $3,246. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Terry Smith Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,141 $135 $40–$426 $132
2022 $4,062 $152 $48–$470 $149
2023 $4,160 $166 $54–$529 $160
2024 $3,352 $173 $55–$556 $164
2025 $3,246 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $4,300 232 payments
  2. Janssen Biotech, Inc. $1,683 80 payments
  3. AbbVie, Inc. $1,658 73 payments
  4. UCB, Inc. $1,499 80 payments
  5. Lilly USA, LLC $1,181 64 payments
  6. Mallinckrodt Hospital Products Inc. $1,056 46 payments
  7. Novartis Pharmaceuticals Corporation $1,011 70 payments
  8. AstraZeneca Pharmaceuticals LP $856 35 payments
  9. GlaxoSmithKline, LLC. $566 33 payments
  10. Pfizer Inc. $471 23 payments
  11. Other $2,680 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,524 829 payments
  2. Education $436 6 payments
Products named General payments · program years 2021–2025
  1. Otezla $2,006 107 payments
  2. TREMFYA $1,999 76 payments
  3. Enbrel Inflammation $1,494 95 payments
  4. Enbrel Inflammation $1,244 75 payments
  5. Cimzia $1,212 68 payments
  6. TALTZ $1,181 64 payments
  7. RINVOQ $1,084 49 payments
  8. ACTHAR $1,056 46 payments
  9. SAPHNELO $805 32 payments
  10. COSENTYX $697 51 payments
  11. Other $7,147 340 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,095

Median for Nurse Practitioner: 389

Drug cost

$1,250,825

Median for Nurse Practitioner: $21,885

Branded share of claims

18%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 51 $377,992
Enbrel Sureclick Etanercept Brand 41 $317,752
Simponi Golimumab Brand 25 $189,143
Tremfya Guselkumab Brand 13 $179,680
Xeljanz Xr Tofacitinib Citrate Brand 12 $71,142
Kevzara Sarilumab Brand 15 $69,270
Hydroxychloroquine Sulfate Generic 397 $14,539
Prednisone Generic 672 $6,029
Methotrexate Methotrexate Sodium Brand 204 $5,336
Febuxostat Generic 28 $3,686

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$120,573

Of which drugs: $7,806

Medicare patients

574

Average age 77

Services billed

4,920

395 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Osteoporosis 36%
Ischemic heart disease 32%
Chronic kidney disease 26%
Depression 24%
Diabetes 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 59 2,347 $229

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $392
$392 41 —
TREMFYA
  • Janssen Biotech, Inc. $366
$366 13 —
Otezla
  • Amgen Inc. $333
$333 — —
SKYRIZI
  • AbbVie, Inc. $289
$289 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $271
$271 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

835 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record